Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230002/S002

Minitouch 3.8 Era System (Minitouch System)

MICROCUBE, LLC · Decision date Jul 13, 2026

FDA DECISIONP230002/S002

What did the FDA approve?

FDA records P230002/S002 as a supplement to PMA P230002, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 13, 2026.

FDA approval order statement

Approval for design modifications to the Minitouch System, including changes to the Handpiece manufacturing methods and changes to the Generator system architecture, hardware, and software to add additional risk control measures and provide an updated user interface.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Obstetrics/Gynecology
Decision date
Jul 13, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P230002/S002
Regulatory pathway
PMA supplement
Product code
MNB
Decision code
APPR
Decision date
Jul 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, thermal ablation, endometrial.

Product code
MNB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230002/S002 received

    Application receipt date recorded by FDA.

  2. P230002/S002 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P230002. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MNB

Product / regulatory recordCompanyPathwayDecision dateSource
Axora Medical, Inc.PMA supplementNov 5, 2026FDA
Channel Medsystems, Inc.PMA supplementNov 3, 2026FDA
Channel Medsystems, Inc.PMA supplementSep 15, 2026FDA
Channel Medsystems, Inc.PMA supplementJul 8, 2026FDA
Axora Medical, Inc.PMA supplementFeb 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MICROCUBE, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
47853 Warm Springs Blvd., Fremont, CA, 94539

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records